Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, has announced that it has entered into a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of Formycon’s Eylea biosimilar FYB203 (Aflibercept) under the brand name Baiama in selected European countries.
This milestone marks Horus Pharma’s entry into the field of biosimilars and further consolidates its position as a comprehensive ophthalmology specialist. The commercialization will cover Horus Pharma’s home market, France, as well as selected European markets.
Expanding Horus Pharma’s portfolio into retina
FYB203/Baiama will be the first biosimilar commercialized by Horus Pharma, underscoring the company’s ambition to expand into new therapeutic areas and strengthen its presence in the retina segment. Horus Pharma already markets a treatment for diabetic macular edema, and with FYB203/Baiama, the company is now able to offer a broader range of therapeutic solutions for retinal pathologies.
This expansion enables Horus Pharma to cover all segments of ophthalmology, from anterior segment and glaucoma to retina, and to address both widespread eye conditions such as age-related macular degeneration, and niche pathologies, thereby responding comprehensively to the needs of patients and healthcare professionals.
“The addition of FYB203/Baiama to our portfolio is a transformative milestone for Horus Pharma,” said Claude Claret, CEO of Horus Pharma. “This is not only our first biosimilar but also a major step in our growth strategy. With Baiama, we reinforce our presence in the retina field and complete our ophthalmology portfolio. Our ambition is to provide patients and practitioners with innovative, safe, and cost-effective therapeutic solutions across the entire spectrum of eye health.”
Medical need in ophthalmology
Retinal diseases such as neovascular age-related macular degeneration (nAMD) are among the leading causes of severe vision loss in Europe, particularly in populations over 65 years old. With demographic changes, the number of patients requiring treatment for such conditions continues to rise.
FYB203 (aflibercept) offers ophthalmologists a cost-efficient alternative to the reference medicine Eylea, as inhibitor of vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel formation in the retina.
The biosimilar received marketing authorization from the European Commission in January 2025 under the brand name Baiama.
Horus Pharma’s European growth
Horus Pharma’s entry into the biosimilar market reflects its commitment to innovation, patient access and sustainability of healthcare systems. Biosimilars introduce competition, reduce costs, and enable more patients to access high-quality therapies.
“By bringing FYB203 to our markets, Horus Pharma will be reinforcing its role as a trusted partner for healthcare professionals and a driver of innovation access in ophthalmology,” added Claude Claret. “We are convinced that biosimilars represent the future of therapeutic access and will play an increasingly central role in the sustainability of healthcare systems.”
